ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Sarepta Therapeutics (SRPT)
Sarepta Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$18.89▲ +5.06%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Sarepta Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Sarepta Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Sarepta Therapeutics a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $16.94 and $20.71; in 9 out of 10, between $14.18 and $24.74. Estimated annual volatility is 60%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $1.8B
- 52-week high
- $24.68
- 52-week low
- $14.68
- Revenue (12 months)
- $2.0B
- Revenue growth (YoY)
- +15.6%
- Earnings growth (YoY)
- -404.7%
- Gross margin
- 61.8%
- Operating margin
- -29.9%
- Net margin
- -32.5%
- Return on equity
- -9.5%
- Free cash flow (12 months)
- $22.1M
- Beta
- 0.26
What this means
ATLAS does not publish a fair value for SRPT right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks SRPT has traded between $14.68 and $24.68. Today it is 23.5% below that high and 29% above its low.
On the business: revenue grew 15.6% year over year; net margin is 32.5%.
Its beta is 0.26: it tends to move less than the market.
About the company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders.
Want to see everything about Sarepta Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Sarepta Therapeutics do?
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders.
What is the chance SRPT goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, SRPT ends the month between $16.94 and $20.71.
How big is Sarepta Therapeutics and what is its P/E ratio?
Sarepta Therapeutics's market capitalization is $1.8B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is SRPT?
ATLAS estimates annual volatility at 60%. In a typical month, half of the outcomes end between $16.94 and $20.71.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer